1,102 results on '"Bashey, Asad"'
Search Results
152. 318 - Outcomes of Cryopreserved Vs Fresh Haploidentical Allogeneic Donor Grafts Using Post-Transplant Cyclophosphamide (PTCy) for Gvhd Prophylaxis
153. Current Status of BoneMarrow Transplantation for Treatment of Cancer
154. Autologous or Allogeneic Stem Cell Transplantation in Patients with Waldenstrom’s Macroglobulinemia
155. Pretransplantation Consolidation Chemotherapy Decreases Leukemia Relapse after Autologous Blood and Bone Marrow Transplants for Acute Myelogenous Leukemia in First Remission
156. Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
157. IMPACT OF CONDITIONING INTENSITY AND GENOMICS ON RELAPSE AFTER ALLOGENEIC TRANSPLANTATION FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME
158. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide
159. A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation
160. Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR
161. Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
162. Incidence and Impact of Non-CMV Herpes Viral Infection in Haploidentical and Matched Sibling Donors Receiving Post-Transplant Cyclophosphamide (PTCy): A CIBMTR Analysis
163. Incidence and Impact of Cytomegalovirus Infection in Haploidentical and Matched-Related Donors Receiving Post-Transplant Cyclophosphamide (PTCy): A CIBMTR Analysis
164. Evaluation of Tacrolimus Levels and Risk of Graft-Versus-Host Disease, Relapse and Non-Relapse Mortality after Haploidentical Transplantation with Post-Transplant Cyclophosphamide
165. Comparison of Transplant Outcomes in Patients with Acute Lymphoblastic Leukemia after Haploidentical Transplant with Post-Transplant Cyclophosphamide or Matched Unrelated Donor Transplant
166. Incidence and Impact of Community Respiratory Viral Infection (CRV) in Haploidentical and Matched Sibling Donors Receiving Post-Transplant Cyclophosphamide (PTCy): A CIBMTR Analysis
167. A Phase II Trial of Melphalan Based Reduced Intensity Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients with Hematologic Malignancies
168. Improved Survival of Patients Diagnosed with Severe (Grade 3-4) Acute GVHD or Severe NIH Grade Chronic GVHD in the Current Era Compared to Historic Controls
169. Real World Outcomes of Letermovir Prophylaxis in Unselected High Risk CMV Seropositive Hematopoietic Stem Cell Transplant Recipients
170. A Phase II Trial Evaluating the Efficacy and Safety of Sargramostim Post Infusion of T -Replete HLA Mismatched Peripheral Blood Haploidentical Hematopoietic Stem Cells with Post Transplant Cyclophosphamide
171. Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor
172. Improved Survival in Patients Who Undergo Relapse of Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation
173. Ixazomib Maintenance to Prevent Alloreactivity and Provide Anti-Malignancy Effects Following Nonmyeloablative T-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide
174. Graft Versus Host Disease (GVHD) after HLA-Mismatched Haploidentical Transplantation with Post-Transplant Cyclophosphamide Compared to Matched Unrelated Donor: Incidence, Distribution and Response to Therapy
175. Psychological and Social Factors Are a Strong Predictor of Survival after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Independent of Disease Risk and Morbidity Score
176. Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort
177. Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations
178. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage–colony-stimulating factor and granulocyte–colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation
179. Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis
180. Immunosuppression with Limited Toxicity: The Characteristics of Nucleoside Analogs and Anti-Lymphocyte Antibodies Used in Nonmyeloablative Hematopoietic Cell Transplantation
181. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry
182. Autologous transplantation for diffuse aggressive Non-Hodgkin lymphoma in first relapse or second remission
183. Adenovirus transduction to effect CD40 signalling improves the immune stimulatory activity of myeloma cells
184. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma
185. 408 - Effect of Early Post-Transplant Respiratory Viral Infections on Graft-Versus-Host Disease (GVHD) and Other Transplant Outcomes
186. 338 - Outcomes of MDS and AML Patients with TP53 Gene Mutation Receiving Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
187. 45 - Allogeneic Hematopoietic Cell Transplantation (HCT) for Adult Patients with Acute Lymphoblastic Leukemia: Impact of Timely Transplantation on Survival Outcomes
188. 24 - Disease-Specific Pathways for NK Cell Alloreactivity Informs Relapse Risk after Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide: Relative Effect of Recipient HLA-C-Group KIR Ligand and HLA-B-Leader Allotype
189. Mobilization of blood-derived stem and progenitor cells in normal subjects by granulocyte-macrophage- and granulocyte-colony-stimulating factors
190. Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT
191. Real-world outcomes of unselected elderly acute myeloid leukemia patients referred to a leukemia/hematopoietic cell transplant program
192. Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report
193. The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation
194. HLA-Matched Sibling Versus Haploidentical Hematopoietic Cell Transplantation (HCT) in Patients with Acute Myeloid Leukemia (AML) in First Complete Remission (CR1)
195. The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation
196. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial
197. The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia
198. Safety and efficacy of rituximab-based first line treatment of chronic GVHD
199. Treatment Patterns and Outcomes of Unselected Elderly Acute Myeloid Leukemia (AML) Patients Referred to a Combined Acute Leukemia and Hematopoietic Stem Cell Transplant (HSCT) Program
200. Long-Term Follow-up of Myeloablative Haploidentical (HID) Peripheral Blood Stem Cell Transplantation and Post-Transplant Cyclophosphamide (PTCy) Following Fludarabine and Total Body Irradiation (TBI)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.